Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Phase 3 data support “changing the current standard of care to now include neoadjuvant and adjuvant pembrolizumab,” according to Ravindra Uppaluri, MD, PhD.

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival.

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma.

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced cervical cancer, according to data presented at Society of Gynecologic ...

Pembrolizumab demonstrated promising efficacy and safety in anaplastic thyroid cancer based on pooled survival and tumor response data.